Capital International LTD Bei Gene, Ltd. Transaction History
Capital International LTD
- $2.09 Billion
- Q2 2024
A detailed history of Capital International LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital International LTD holds 74,692 shares of BGNE stock, worth $15.1 Million. This represents 0.51% of its overall portfolio holdings.
Number of Shares
74,692
Previous 74,874
0.24%
Holding current value
$15.1 Million
Previous $11.7 Million
8.99%
% of portfolio
0.51%
Previous 0.58%
Shares
17 transactions
Others Institutions Holding BGNE
# of Institutions
217Shares Held
42.1MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.14 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.42 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.05 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.01 Billion0.52% of portfolio
-
Baillie Gifford & CO3.71MShares$750 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $21B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...